ArticleArchives of toxicology2026
Reassessing the carcinogenic potential of dibutyl hydrogen phosphate: new insight from repeated-dose toxicity studies.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Dibutyl hydrogen phosphate (DBP) has a self-classification as suspected rat urinary bladder carcinogen. Substance-specific repeated-dose toxicity or carcinogenicity data are unavailable for DBP, which is generally only present in multi-constituent substances (MCS) and mixtures. The suspected carcinogenicity of DBP is based on read-across to tributyl phosphate (TBP), which has a harmonised classification (Carcinogenicity Category 2) as non-genotoxic carcinogen since it may cause bladder tumours in Sprague-Dawley rats. DBP and TBP have irritant properties, and bladder lesions following (sub-)chronic exposure to TBP are considered a result of sustained irritation possibly caused by DBP, as DBP is the major metabolite of TBP and eliminated via urine. To further explore the toxicological properties of DBP, two test guideline-conforming oral repeated-dose toxicity studies are presented here. Wistar rats were administered MCS-41D-0.8T (41.3% DBP, 0.8% TBP). After 28- and 90-day exposure to 50−1000 and 50–400 mg/kg body weight/day, respectively, of MCS-41D-0.8T, there were no observable (pre-)carcinogenic bladder lesions, such as reported after similar exposures to TBP or the technical mixture Mix-62D-19T (62% DBP, 19% TBP). Supported by kinetic considerations and in silico predictions, the weight-of-evidence indicates that orally administered DBP does not elicit the characteristic chemical irritation associated with TBP exposure and that the (pre-)carcinogenic effects observed upon exposure to TBP or Mix-62D-19T are caused by TBP and/or its metabolites in the bladder. Hence, distinct kinetic and physiological fates were observed for orally administered DBP versus TBP, indicating that orally administered DBP is not a rat carcinogen. This challenges the current self-classification of DBP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.